325 39. 一pryoog7022pood20208 PMD22649104(htp pubmed/22649104.doi10.1182 blood-2012.01-380139 40 0642pMD216292860h bmed/21629 286).doit10.1038/mrd3463ps:/doi.org10.1038%2Fnrd3463 (.ni for metastati rch.17 articles/PMC3575079) 1900389).doi:10.1158/1078-0432.CCR-11 ising immunotherapy for melanoma' ncology.24(14):128 -8.PMID 21294471(https:/www.ncbi.nlm.nih.gov/pubmed/21294471) 43 ns MS,Eg nd mG 19:56.PMID(hups vww.ncbi.nlm.nih.gov/pubmed/11244047). (https://do.on .1146%2Fannurev.immunol.19.1.565 4 resistant to previous the 8.PMC 32 337)a 45g102147 i.nlm. 7284(hups:/do .57284 ang "Ofatumumab"(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726602). -212 .8895 (hutps: doi.org/10.4161%2 Fmabs.1,4.8895 46 (https://www.ncbi.nlm.nih.g pubmed/20614951).dot10.2165/11201110-000000000-00000htps:/d0 org10.2165%2F113 00000-00000 6381:80343pMD12662126htD n-Hodgkin's d26226.a010216506349s520363080.00095peoo70.216s2ro0034992088630 "Mochanism of action c rituximab" Anti-Cancer Drugs.13 Su yC Travers p Wal ort M.Shlomchik M(2001)Immunobioloay:Fifth Edition (https://www.ncb i.nlm.nih.gov/books/bv.fcgi? all-bv.View..Sh WTOC&rid=imm.TOC&depth=10).New York and 01 12010)."Rit ncbi.nlm nih. PMC2848172). in hem .47(2):115-23.PMC2848172(https://www.ncbi.nlm.nih.gov/ 48172 (http//www.nc gov/pubme 001011 51.Dranoff G (January 2004) MID1470802 ww.ncbi.nlm.nih.gov/pubmed/14708024). 52.6l0038nc1252 CM.Schreiber RD (No ember 2006 6片8 48.PMID 17063185(https://www.ncbi.nlm. ord in cance immunotherapy"(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235441)Clinical& pWD22190970 35441)a 0i.0rg/10.1155%2F2011%2F349575)